Cure8 news brief
This suggests an existing antibiotic, vancomycin, may help a specific group of IBD patients who also have primary sclerosing cholangitis (PSC), including some who did not respond to other IBD treatments. If confirmed in randomized trials, it could become a new therapeutic option for PSC-IBD.
Adults with IBD and PSC, clinicians treating PSC-IBD, researchers studying microbiome–metabolome links in IBD, and patients interested in emerging treatment research.
This news report summarizes a University of Birmingham-led open-label clinical study testing oral vancomycin in people who have inflammatory bowel disease (IBD) in the setting of primary sclerosing cholangitis (PSC).
According to the article, 80% of participants reached clinical remission after four weeks of vancomycin and all showed mucosal healing, but symptoms returned after stopping treatment. The researchers plan a randomized controlled trial next.
The study also linked vancomycin use to changes in bile acids and host–microbiome–metabolomic signatures; investigators say these findings are being followed up to understand mechanisms and refine treatments. The trial was supported by ECCO and NIHR-affiliated research centers and published in the Journal of Crohn's and Colitis.
No treatment recommendations are made in the source. The article describes preliminary clinical results from an open-label study; the authors and news item note that randomized trials are needed to confirm therapeutic benefit and safety.
Findings are from an open-label study with short treatment and follow-up; symptoms reportedly returned after stopping vancomycin. The article and authors emphasize the need for randomized controlled trials to determine efficacy, safety, and durability before clinical use changes.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study reports that upadacitinib produced clinical responses and steroid-free remission in a majority of patients with refractory Crohn's disease at 12 weeks, which may be relevant for people who have not responded...
The study suggests upadacitinib may improve both symptoms and MRI‑documented healing of perianal fistulas in Crohn’s disease, offering a potential treatment option especially for patients who have not previously received...
Perianal fistulas are serious, hard-to-treat complications in pediatric Crohn disease. The study suggests starting anti-TNFα therapy early — especially for kids with perianal lesions — may lower the chance of developing...
